AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Fersis Bacteriophage specifically targets certain bacterial species, potentially aiding in the treatment of infections caused by those bacteria. The effectiveness of bacteriophage therapy depends on factors such as the susceptibility of the bacterial strain to the phage and the ability of the phage to effectively lyse (destroy) the bacteria.
Antibiotic Resistance: Bacteriophages can target and kill antibiotic-resistant bacteria, including multidrug-resistant strains. This makes them a potential treatment option for infections that do not respond to traditional antibiotic therapy.
Specificity: Bacteriophages are highly specific to particular bacterial strains or species, which can be advantageous in targeting pathogenic bacteria while minimizing disruption to beneficial bacteria in the body's microbiota. This specificity may help reduce the risk of dysbiosis (microbial imbalance) compared to broad-spectrum antibiotics.
Safety: Bacteriophages are generally considered safe for human use and have been used in some countries for decades in certain medical and veterinary applications. However, as with any medical intervention, safety considerations, including the potential for adverse effects or unintended consequences, need to be carefully evaluated.
Potential Challenges: While bacteriophage therapy shows promise, several challenges need to be addressed for its widespread use, including issues related to phage stability, production, purification, delivery methods, and regulatory approval processes.
Combination Therapy: Bacteriophage therapy can be used alone or in combination with antibiotics or other antimicrobial agents. Combining bacteriophages with antibiotics may help overcome antibiotic resistance and enhance treatment efficacy.
Research and Development: Ongoing research is focused on further understanding the mechanisms of bacteriophage action, optimizing phage selection and formulation, developing delivery methods, and conducting clinical trials to evaluate safety and efficacy in various medical conditions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Streptococcus thermophilus | Reduces |
| strain | Streptococcus salivarius K12 | Reduces |
| strain | Streptococcus salivarius M18 | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 1 | 1 | |
| ADHD | 1 | 1 | |
| Allergic Rhinitis (Hay Fever) | 2.2 | 0.8 | 1.75 |
| Allergies | 1.1 | 0.5 | 1.2 |
| Allergy to milk products | 0.5 | 0.5 | 0 |
| Alzheimer's disease | 1 | 0.5 | 1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.5 | |
| Ankylosing spondylitis | 1.8 | 1.8 | |
| Anorexia Nervosa | 1 | 0.5 | 1 |
| Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
| Asthma | 3.2 | 1 | 2.2 |
| Atrial fibrillation | 1.1 | 1.1 | |
| Autism | 1.5 | 0.5 | 2 |
| Autoimmune Disease | 0.5 | 0.5 | |
| Barrett esophagus cancer | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.5 | 0.5 | |
| Biofilm | 3.7 | 3.7 | |
| Brain Trauma | 1 | 0.5 | 1 |
| Cancer (General) | 0.8 | -0.8 | |
| Carcinoma | 0.5 | 0.5 | |
| Celiac Disease | 2 | 1 | 1 |
| Cerebral Palsy | 0.5 | 0.5 | |
| Chronic Fatigue Syndrome | 0.6 | 0.5 | 0.2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3.6 | 0.5 | 6.2 |
| Chronic Urticaria (Hives) | 0.5 | 0.5 | |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1 | 0.7 |
| Cognitive Function | 0.5 | 0.5 | 0 |
| Colorectal Cancer | 2 | 2 | |
| Coronary artery disease | 1 | 1 | |
| COVID-19 | 4 | 1.2 | 2.33 |
| Crohn's Disease | 1.6 | 0.1 | 15 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | 0.5 | |
| cystic fibrosis | 0.5 | 0.5 | |
| d-lactic acidosis (one form of brain fog) | 0.7 | 0.7 | |
| deep vein thrombosis | 1 | 1 | 0 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 1.4 | 0.5 | 1.8 |
| Dermatomyositis | 1 | 1 | |
| Eczema | 2 | 1 | 1 |
| Endometriosis | 1 | 1 | |
| Eosinophilic Esophagitis | 0.5 | -0.5 | |
| Epilepsy | 0.7 | 0.7 | |
| erectile dysfunction | 0.1 | -0.1 | |
| Fibromyalgia | 0.5 | 0.5 | |
| Functional constipation / chronic idiopathic constipation | 1.1 | 1.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.5 | -1.5 |
| Generalized anxiety disorder | 0.5 | 0.5 | 0 |
| Glioblastoma | 0.5 | -0.5 | |
| Gout | 1 | 1 | |
| Graves' disease | 0 | 0.5 | 0 |
| Gulf War Syndrome | 0.5 | 0.5 | |
| Halitosis | 0.5 | 0.5 | 0 |
| Heart Failure | 2.2 | 0.3 | 6.33 |
| Hidradenitis Suppurativa | 2.1 | 2.1 | |
| High Histamine/low DAO | 1 | 1 | |
| hyperglycemia | 1.5 | 1.5 | |
| hypersomnia | 0.5 | 0.1 | 4 |
| hypertension (High Blood Pressure | 1.1 | 1.1 | 0 |
| Hypothyroidism | 1 | 1 | |
| IgA nephropathy (IgAN) | 1.1 | 1.1 | |
| Inflammatory Bowel Disease | 1.6 | 0.8 | 1 |
| Insomnia | 2 | 1 | 1 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 1.1 | 0.5 | 1.2 |
| ischemic stroke | 0.5 | 0.1 | 4 |
| Liver Cirrhosis | 2.4 | 1.1 | 1.18 |
| Long COVID | 1.3 | 1.3 | |
| Low bone mineral density | 0.1 | 0.1 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 1.5 | 1.5 | |
| ME/CFS with IBS | 0.5 | 0.5 | |
| ME/CFS without IBS | 0.5 | 0.5 | |
| membranous nephropathy | 0.5 | 0.5 | |
| Menopause | 0.5 | 0.5 | |
| Metabolic Syndrome | 1.1 | 1.1 | 0 |
| Mood Disorders | 1.6 | 0.5 | 2.2 |
| multiple chemical sensitivity [MCS] | 1.3 | 1.3 | |
| Multiple Sclerosis | 2.1 | 0.5 | 3.2 |
| Multiple system atrophy (MSA) | 0.4 | 0.4 | |
| myasthenia gravis | 0.5 | 0.5 | |
| neuropathic pain | 0 | 0 | |
| Neuropathy (all types) | 0.5 | 0.5 | |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 1 | |
| Obesity | 1.2 | 1.5 | -0.25 |
| obsessive-compulsive disorder | 1.5 | 0.5 | 2 |
| Osteoarthritis | 1 | 0.5 | 1 |
| Osteoporosis | 0.5 | 0.5 | 0 |
| pancreatic cancer | 1.5 | 0.5 | 2 |
| Parkinson's Disease | 3 | 1.3 | 1.31 |
| Polycystic ovary syndrome | 1.4 | 0.5 | 1.8 |
| primary biliary cholangitis | 0.5 | 0.8 | -0.6 |
| Primary sclerosing cholangitis | 0.9 | 0.9 | |
| Psoriasis | 2.3 | 2.3 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 0.6 | 2.33 |
| Rosacea | 1 | 1 | |
| Schizophrenia | 1.3 | 1.3 | |
| scoliosis | 0.5 | 0.5 | |
| sensorineural hearing loss | 1.2 | 1.2 | |
| Sjögren syndrome | 0.5 | 0.5 | |
| Sleep Apnea | 0 | 0 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 1 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.8 | |
| Systemic Lupus Erythematosus | 1.5 | 1.5 | |
| Tic Disorder | 1 | 0 | 0 |
| Tourette syndrome | 1 | 1 | |
| Type 1 Diabetes | 1 | 1 | 0 |
| Type 2 Diabetes | 1.1 | 1 | 0.1 |
| Ulcerative colitis | 1.7 | 1.7 | |
| Unhealthy Ageing | 0.5 | 0.5 | |
| Vitiligo | 0.5 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
